Mauricio García-Mora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mauricio García-Mora has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Esperanza Diaz Casas
Functional Unit for Breast and Soft Tissue Tumors, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
11 shared publications - Iván Fernando Mariño Lozano
Functional Unit for Breast and Soft Tissue Tumors, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
10 shared publications - Ximena Briceño-Morales
Departamento de Cirugía, Facultad de Medicina, Universidad Nacional de Colombia—Sede Bogotá, Bogotá, Colombia
10 shared publications - Carlos Duarte
Functional Unit for Breast and Soft Tissue Tumors, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
9 shared publications - Carlos Lehmann Mosquera
Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
7 shared publications - Javier Ángel Aristizabal
Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
7 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Asociacion Latinoamericana para el Avance de la Ciencia in Ciencia Latina Revista Científica Multidisciplinar
- Vol. 10 (4) , 2213-2226
Espiradenoma cutáneo de gran tamaño y localización perineal e inguinoescrotal con diagnóstico preoperatorio de adenocarcinoma de glándulas anales: reporte de caso
El espiradenoma cutáneo es una neoplasia anexial benigna poco frecuente, generalmente pequeña y localizada en cabeza, cuello o tronco. Las presentaciones perineales e inguinoescrotales son excepcionales y pueden representar un importante reto diagnóstico cuando la evolución clínica, los hallazgos por imagen y las muestras histológicas limitadas sugieren una neoplasia maligna. Presentación del caso Se presenta el caso de un paciente masculino en la séptima década de la vida con una lesión pediculada localizada en el pliegue inguinoescrotal derecho, de cuatro años de evolución y crecimiento acelerado durante los últimos cuatro meses. La resonancia magnética mostró una lesión heterogénea con realce posterior a la administración de contraste y un componente central sugestivo de necrosis. La biopsia percutánea complementada con inmunohistoquímica fue interpretada como compatible con adenocarcinoma de glándulas anales. El caso fue discutido en junta multidisciplinaria, que recomendó resección local amplia con criterio oncológico y objetivo de obtener márgenes negativos. El estudio histopatológico definitivo confirmó un espiradenoma cutáneo con márgenes quirúrgicos negativos. Conclusión La discrepancia entre el diagnóstico preoperatorio y el diagnóstico definitivo no invalida una conducta terapéutica sustentada en la mejor evidencia disponible. Este caso resalta la importancia de integrar la información clínica, radiológica e histopatológica durante la toma de decisiones, evidencia las limitaciones del muestreo histológico parcial en tumores anexiales de arquitectura compleja y reafirma el papel de la resección quirúrgica como procedimiento diagnóstico y terapéutico en lesiones con alta sospecha de malignidad.
- 21 July 2026
- Published by Asociacion Latinoamericana para el Avance de la Ciencia in Ciencia Latina Revista Científica Multidisciplinar
- Vol. 10 (4) , 2213-2226
Open AccessEspiradenoma cutáneo de gran tamaño y localización perineal e inguinoescrotal con diagnóstico preoperatorio de adenocarcinoma de glándulas anales: reporte de caso
El espiradenoma cutáneo es una neoplasia anexial benigna poco frecuente, generalmente pequeña y localizada en cabeza, cuello o tronco. Las presentaciones perineales e inguinoescrotales son excepcionales y pueden representar un importante reto diagnóstico cuando la evolución clínica, los hallazgos por imagen y las muestras histológicas limitadas sugieren una neoplasia maligna. Presentación del caso Se presenta el caso de un paciente masculino en la séptima década de la vida con una lesión pediculada localizada en el pliegue inguinoescrotal derecho, de cuatro años de evolución y crecimiento acelerado durante los últimos cuatro meses. La resonancia magnética mostró una lesión heterogénea con realce posterior a la administración de contraste y un componente central sugestivo de necrosis. La biopsia percutánea complementada con inmunohistoquímica fue interpretada como compatible con adenocarcinoma de glándulas anales. El caso fue discutido en junta multidisciplinaria, que recomendó resección local amplia con criterio oncológico y objetivo de obtener márgenes negativos. El estudio histopatológico definitivo confirmó un espiradenoma cutáneo con márgenes quirúrgicos negativos. Conclusión La discrepancia entre el diagnóstico preoperatorio y el diagnóstico definitivo no invalida una conducta terapéutica sustentada en la mejor evidencia disponible. Este caso resalta la importancia de integrar la información clínica, radiológica e histopatológica durante la toma de decisiones, evidencia las limitaciones del muestreo histológico parcial en tumores anexiales de arquitectura compleja y reafirma el papel de la resección quirúrgica como procedimiento diagnóstico y terapéutico en lesiones con alta sospecha de malignidad.
- Open Access
- 23 January 2026
- Published by Asociacion Latinoamericana para el Avance de la Ciencia in Ciencia Latina Revista Científica Multidisciplinar
- Vol. 10 (1) , 202-217
Retroperitoneal synovial sarcoma a diagnostic challenge: an uncommon case
Synovial sarcoma (SS) is a rare and aggressive mesenchymal neoplasm that can arise at various anatomical sites. However, it typically occurs in the soft tissues of the extremities, particularly the lower limbs [1]. This tumor makes up 0.8%-10% of soft tissue sarcomas and about 1% of reported retroperitoneal tumors. [2,3,4]. Its highest incidence is observed in young adults, with no clear differences by sex. Because of its low frequency, epidemiological data are primarily derived from isolated reports and small series. [2,3,4,5]. Although its name suggests a synovial origin, the tumor does not develop from the synovial membrane; the term is kept because of morphological similarities to embryonic synovium [6,7]. Its diagnosis is difficult, not only because it can resemble benign lesions, but also because of morphological overlap with other sarcomas. When it occurs in the retroperitoneum, its detection is often delayed because this anatomical space allows for progressive tumor growth without specific symptoms. Retroperitoneal lesions can resemble other aggressive neoplasms; this complicates differential diagnosis and leads to significant treatment delays, which negatively affect prognosis. In this context, most retroperitoneal cases are detected at advanced stages and are linked to lower survival rates, estimated at 20%-29% at five years [4, 6].Retroperitoneal SS is extremely rare, with fewer than 35 cases documented in the literature [4,5]. Spinal involvement is exceptional, and most reports lack or have limited follow-up [2]. Due to the absence of standardized guidelines for retroperitoneal SS—the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO) include this tumor within the general management of soft tissue sarcomas—its approach, diagnosis, and treatment pose a challenge for surgeons [1,2].
- 23 January 2026
- Published by Asociacion Latinoamericana para el Avance de la Ciencia in Ciencia Latina Revista Científica Multidisciplinar
- Vol. 10 (1) , 202-217
Open AccessRetroperitoneal synovial sarcoma a diagnostic challenge: an uncommon case
Synovial sarcoma (SS) is a rare and aggressive mesenchymal neoplasm that can arise at various anatomical sites. However, it typically occurs in the soft tissues of the extremities, particularly the lower limbs [1]. This tumor makes up 0.8%-10% of soft tissue sarcomas and about 1% of reported retroperitoneal tumors. [2,3,4]. Its highest incidence is observed in young adults, with no clear differences by sex. Because of its low frequency, epidemiological data are primarily derived from isolated reports and small series. [2,3,4,5]. Although its name suggests a synovial origin, the tumor does not develop from the synovial membrane; the term is kept because of morphological similarities to embryonic synovium [6,7]. Its diagnosis is difficult, not only because it can resemble benign lesions, but also because of morphological overlap with other sarcomas. When it occurs in the retroperitoneum, its detection is often delayed because this anatomical space allows for progressive tumor growth without specific symptoms. Retroperitoneal lesions can resemble other aggressive neoplasms; this complicates differential diagnosis and leads to significant treatment delays, which negatively affect prognosis. In this context, most retroperitoneal cases are detected at advanced stages and are linked to lower survival rates, estimated at 20%-29% at five years [4, 6].Retroperitoneal SS is extremely rare, with fewer than 35 cases documented in the literature [4,5]. Spinal involvement is exceptional, and most reports lack or have limited follow-up [2]. Due to the absence of standardized guidelines for retroperitoneal SS—the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO) include this tumor within the general management of soft tissue sarcomas—its approach, diagnosis, and treatment pose a challenge for surgeons [1,2].
- Open Access
- 1 January 2026
- Published by Bioscientifica in Endocrine Oncology
- Vol. 6 (1)
Current evidence across the treatment spectrum of adrenocortical carcinoma: a comprehensive scoping review
Adrenocortical carcinoma is a rare and aggressive malignancy for which high-quality evidence to guide clinical decision-making remains limited. This scoping review aimed to map and synthesize the extent, nature, and direction of evidence across five therapeutic domains in the management of adrenocortical carcinoma. Following the Joanna Briggs Institute methodology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidance, MEDLINE, Embase, and the Cochrane Library were searched without date restrictions. Eligible sources included clinical trials, observational studies, systematic reviews, and clinical guidelines addressing any treatment modality for adrenocortical carcinoma. Data were extracted using a standardized form and synthesized narratively across domains. Evidence visualizations and an intervention-by-domain matrix were developed to identify areas of consistency, uncertainty, and research gaps. Forty-nine studies met the inclusion criteria. Complete tumor resection with negative margins consistently emerged as the strongest prognostic factor. Minimally invasive adrenalectomy showed comparable outcomes only in carefully selected low-risk patients. Adjuvant mitotane demonstrated potential benefit in high-risk disease but not in low- to intermediate-risk patients. In metastatic disease, multimodal management incorporating etoposide, doxorubicin, cisplatin, and mitotane, together with metastasectomy and local therapies, was associated with improved outcomes in selected cases. Recurrence was frequent and often occurred early, particularly in large or invasive tumors. Cortisol-secreting tumors were associated with higher postoperative morbidity and earlier recurrence. Although the available evidence is predominantly retrospective and heterogeneous, consistent patterns emerge that can inform clinical management. This review provides a structured evidence base for future consensus development and highlights priorities for further research.
- 1 January 2026
- Published by Bioscientifica in Endocrine Oncology
- Vol. 6 (1)
Open AccessCurrent evidence across the treatment spectrum of adrenocortical carcinoma: a comprehensive scoping review
Adrenocortical carcinoma is a rare and aggressive malignancy for which high-quality evidence to guide clinical decision-making remains limited. This scoping review aimed to map and synthesize the extent, nature, and direction of evidence across five therapeutic domains in the management of adrenocortical carcinoma. Following the Joanna Briggs Institute methodology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidance, MEDLINE, Embase, and the Cochrane Library were searched without date restrictions. Eligible sources included clinical trials, observational studies, systematic reviews, and clinical guidelines addressing any treatment modality for adrenocortical carcinoma. Data were extracted using a standardized form and synthesized narratively across domains. Evidence visualizations and an intervention-by-domain matrix were developed to identify areas of consistency, uncertainty, and research gaps. Forty-nine studies met the inclusion criteria. Complete tumor resection with negative margins consistently emerged as the strongest prognostic factor. Minimally invasive adrenalectomy showed comparable outcomes only in carefully selected low-risk patients. Adjuvant mitotane demonstrated potential benefit in high-risk disease but not in low- to intermediate-risk patients. In metastatic disease, multimodal management incorporating etoposide, doxorubicin, cisplatin, and mitotane, together with metastasectomy and local therapies, was associated with improved outcomes in selected cases. Recurrence was frequent and often occurred early, particularly in large or invasive tumors. Cortisol-secreting tumors were associated with higher postoperative morbidity and earlier recurrence. Although the available evidence is predominantly retrospective and heterogeneous, consistent patterns emerge that can inform clinical management. This review provides a structured evidence base for future consensus development and highlights priorities for further research.
- Open Access
Oncological Outcomes of De-Escalation of Axillary Surgery in Breast Cancer Patients at a Referral Cancer Center in Colombia
Background/Objectives: De-escalation of axillary surgery with sentinel lymph node biopsy (SLNB) has been shown to decrease morbidity in breast cancer patients without affecting oncological outcomes. However, there are very few reports on its applicability in real-world clinical practice, especially in middle-income countries. Methods: A retrospective historical cohort study was conducted, including 787 patients with clinical stage I–IIIA breast cancer treated from 2013 to 2023 at the INC in Colombia. Two groups were analyzed based on the timing of the axillary procedure: patients undergoing SLNB as initial surgery (Upfront SLNB) and those receiving neoadjuvant chemotherapy (Post-NACT SLNB). Results: The overall sentinel lymph node (SLN) identification rate was 99.3%. SLN positivity was 32% in Upfront SLNB and 13.1% in Post-NACT SLNB. Axillary lymph node dissection (ALND) was omitted in 56% of patients with node-positive Upfront SLNB; it was avoided in 86.8% of the Post-NACT group with complete axillary response (ypN0). Regional recurrence rates were 2.33%. In multivariate analysis, the main factors linked to recurrence and mortality were triple-negative and luminal B HER2-negative biological subtypes, histological grade 2, and tumor size ≥ 2 cm. At 60 months of follow-up, 91.4% (95% CI: 88.9–93.9) of patients remained recurrence-free (time-recurrence (TR)), and overall survival (OS) was 96.1% (95% CI: 94.5–97.7), with no differences observed based on the axillary surgical strategy. Conclusions: Sentinel lymph node biopsy (SLNB) is an oncologically safe procedure for patients with early-stage and locally advanced breast cancer with an adequate response to neoadjuvant systemic treatment.
Open AccessOncological Outcomes of De-Escalation of Axillary Surgery in Breast Cancer Patients at a Referral Cancer Center in Colombia
Background/Objectives: De-escalation of axillary surgery with sentinel lymph node biopsy (SLNB) has been shown to decrease morbidity in breast cancer patients without affecting oncological outcomes. However, there are very few reports on its applicability in real-world clinical practice, especially in middle-income countries. Methods: A retrospective historical cohort study was conducted, including 787 patients with clinical stage I–IIIA breast cancer treated from 2013 to 2023 at the INC in Colombia. Two groups were analyzed based on the timing of the axillary procedure: patients undergoing SLNB as initial surgery (Upfront SLNB) and those receiving neoadjuvant chemotherapy (Post-NACT SLNB). Results: The overall sentinel lymph node (SLN) identification rate was 99.3%. SLN positivity was 32% in Upfront SLNB and 13.1% in Post-NACT SLNB. Axillary lymph node dissection (ALND) was omitted in 56% of patients with node-positive Upfront SLNB; it was avoided in 86.8% of the Post-NACT group with complete axillary response (ypN0). Regional recurrence rates were 2.33%. In multivariate analysis, the main factors linked to recurrence and mortality were triple-negative and luminal B HER2-negative biological subtypes, histological grade 2, and tumor size ≥ 2 cm. At 60 months of follow-up, 91.4% (95% CI: 88.9–93.9) of patients remained recurrence-free (time-recurrence (TR)), and overall survival (OS) was 96.1% (95% CI: 94.5–97.7), with no differences observed based on the axillary surgical strategy. Conclusions: Sentinel lymph node biopsy (SLNB) is an oncologically safe procedure for patients with early-stage and locally advanced breast cancer with an adequate response to neoadjuvant systemic treatment.
- Open Access
- 22 September 2025
- Published by Asociacion Latinoamericana para el Avance de la Ciencia in Ciencia Latina Revista Científica Multidisciplinar
- Vol. 9 (5) , 15382-15408
Calidad de Vida Relacionada con la Salud en Pacientes Oncológicos: Revisión de la Literatura 2020–2025
Introducción: El cáncer representa una de las principales causas de carga global de enfermedad, y su creciente supervivencia ha desplazado el foco hacia la calidad de vida relacionada con la salud (HRQoL) como indicador esencial del bienestar del paciente. La HRQoL integra dimensiones físicas, emocionales, sociales y funcionales, y su medición mediante instrumentos validados se ha convertido en un componente clave de la práctica oncológica contemporánea. Objetivo: Describir la evidencia reciente (2020–2025) sobre HRQoL en adultos con cáncer, los instrumentos más utilizados y los factores asociados a su variación. Métodos: Revisión narrativa de literatura en PubMed, Scopus, Web of Science y SciELO, incluyendo estudios en inglés o español publicados entre 2020 y 2025 que evaluaron HRQoL con instrumentos validados (EORTC QLQ-C30, FACT-G, EQ-5D, PROMIS). Resultados: Se incluyeron 18 estudios multicéntricos y regionales. El EORTC QLQ-C30 fue el instrumento más empleado, seguido de FACT-G, EQ-5D-5L y PROMIS. Los dominios físicos suelen recuperarse tras el tratamiento, mientras que los emocionales y sociales permanecen más afectados. Factores como estadio avanzado, toxicidad, ansiedad y bajo nivel socioeconómico se asociaron con peor HRQoL. La puntuación resumen del QLQ-C30 mostró valor pronóstico en supervivencia. Intervenciones como rehabilitación oncológica, psico-oncología y tele-PROMs demostraron mejoras clínicamente significativas. Conclusión: La HRQoL se consolidó entre 2020–2025 como un indicador clínico y pronóstico esencial en oncología. Se requieren más estudios longitudinales y validaciones regionales, especialmente en América Latina.
- 22 September 2025
- Published by Asociacion Latinoamericana para el Avance de la Ciencia in Ciencia Latina Revista Científica Multidisciplinar
- Vol. 9 (5) , 15382-15408
Open AccessCalidad de Vida Relacionada con la Salud en Pacientes Oncológicos: Revisión de la Literatura 2020–2025
Introducción: El cáncer representa una de las principales causas de carga global de enfermedad, y su creciente supervivencia ha desplazado el foco hacia la calidad de vida relacionada con la salud (HRQoL) como indicador esencial del bienestar del paciente. La HRQoL integra dimensiones físicas, emocionales, sociales y funcionales, y su medición mediante instrumentos validados se ha convertido en un componente clave de la práctica oncológica contemporánea. Objetivo: Describir la evidencia reciente (2020–2025) sobre HRQoL en adultos con cáncer, los instrumentos más utilizados y los factores asociados a su variación. Métodos: Revisión narrativa de literatura en PubMed, Scopus, Web of Science y SciELO, incluyendo estudios en inglés o español publicados entre 2020 y 2025 que evaluaron HRQoL con instrumentos validados (EORTC QLQ-C30, FACT-G, EQ-5D, PROMIS). Resultados: Se incluyeron 18 estudios multicéntricos y regionales. El EORTC QLQ-C30 fue el instrumento más empleado, seguido de FACT-G, EQ-5D-5L y PROMIS. Los dominios físicos suelen recuperarse tras el tratamiento, mientras que los emocionales y sociales permanecen más afectados. Factores como estadio avanzado, toxicidad, ansiedad y bajo nivel socioeconómico se asociaron con peor HRQoL. La puntuación resumen del QLQ-C30 mostró valor pronóstico en supervivencia. Intervenciones como rehabilitación oncológica, psico-oncología y tele-PROMs demostraron mejoras clínicamente significativas. Conclusión: La HRQoL se consolidó entre 2020–2025 como un indicador clínico y pronóstico esencial en oncología. Se requieren más estudios longitudinales y validaciones regionales, especialmente en América Latina.
- Open Access
Oncologic Outcomes of Breast-Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Background: Breast-conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with non-metastatic breast cancer at a referral cancer center in a medium-resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as the initial treatment and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow-up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were a locally advanced clinical stage (HR 5.13; p = 0.01), triple-negative subtype (HR 8.02; p < 0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p < 0.01). Conclusions: Breast-conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. The time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.
Open AccessOncologic Outcomes of Breast-Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Background: Breast-conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with non-metastatic breast cancer at a referral cancer center in a medium-resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as the initial treatment and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow-up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were a locally advanced clinical stage (HR 5.13; p = 0.01), triple-negative subtype (HR 8.02; p < 0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p < 0.01). Conclusions: Breast-conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. The time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.
- Open Access
- 7 February 2025
- Published by MDPI AG in Preprints.org
Oncologic Outcomes of Breast‐Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Background: Breast‐conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with nonmetastatic breast cancer at a referral cancer center in a medium‐resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as initial treatment, and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow‐up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were locally advanced clinical stage (HR 5.13; p =0.01), triple‐negative subtype (HR 8.02; p <0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p <0.01). Conclusions: Breast‐conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. Time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.
- 7 February 2025
- Published by MDPI AG in Preprints.org
Open AccessOncologic Outcomes of Breast‐Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Background: Breast‐conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with nonmetastatic breast cancer at a referral cancer center in a medium‐resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as initial treatment, and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow‐up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were locally advanced clinical stage (HR 5.13; p =0.01), triple‐negative subtype (HR 8.02; p <0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p <0.01). Conclusions: Breast‐conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. Time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.
- Open Access
Management and Clinical Outcomes of Breast Cancer in Women Diagnosed with Hereditary Cancer Syndromes in a Clinic-Based Sample from Colombia
This study aimed to investigate prognosis and survival differences in 82 breast cancer patients with germline pathogenic/likely pathogenic variants (PVs) treated and followed at the Breast Unit of the Instituto Nacional de Cancerología, Colombia (INC-C) between 2018 and 2021. Median age at diagnosis was 46 years, with 62.2% presenting locally advanced tumors, 47.6% histological grade 3, and 35.4% with triple-negative breast cancer (TNBC) subtype. Most carriers, 74.4% (61/82), had PVs in known breast cancer susceptibility genes (i.e., “associated gene carriers” group, considered inherited breast cancer cases): BRCA2 (30), BRCA1 (14), BARD1 (4), RAD51D (3), TP53 (2), PALB2 (2), ATM (2), CHEK2 (1), RAD51C (1), NF1 (1), and PTEN (1). BRCA1-2 represented 53.7%, and homologous recombination DNA damage repair (HR-DDR) genes associated with breast cancer risk accounted for 15.9%. Patients with PVs in non-breast-cancer risk genes were combined in a different category (21/82; 25.6%) (i.e., “non-associated gene carriers” group, considered other breast cancer cases). Median follow-up was 38.1 months, and 24% experienced recurrence, with 90% being distant. The 5-year Disease-Free Survival (DFS) for inherited breast cancer cases was 66.5%, and for other breast cancer cases it was 88.2%. In particular, for carriers of PVs in the BRCA2 gene, it was 37.6%. The 5-year Overall Survival (OS) rates ranged from 68.8% for those with PVs in BRCA2 to 100% for those with PVs in other HR-DDR genes. Further studies are crucial for understanding tumor behavior and therapy response differences among Colombian breast cancer patients with germline PVs.
Open AccessManagement and Clinical Outcomes of Breast Cancer in Women Diagnosed with Hereditary Cancer Syndromes in a Clinic-Based Sample from Colombia
This study aimed to investigate prognosis and survival differences in 82 breast cancer patients with germline pathogenic/likely pathogenic variants (PVs) treated and followed at the Breast Unit of the Instituto Nacional de Cancerología, Colombia (INC-C) between 2018 and 2021. Median age at diagnosis was 46 years, with 62.2% presenting locally advanced tumors, 47.6% histological grade 3, and 35.4% with triple-negative breast cancer (TNBC) subtype. Most carriers, 74.4% (61/82), had PVs in known breast cancer susceptibility genes (i.e., “associated gene carriers” group, considered inherited breast cancer cases): BRCA2 (30), BRCA1 (14), BARD1 (4), RAD51D (3), TP53 (2), PALB2 (2), ATM (2), CHEK2 (1), RAD51C (1), NF1 (1), and PTEN (1). BRCA1-2 represented 53.7%, and homologous recombination DNA damage repair (HR-DDR) genes associated with breast cancer risk accounted for 15.9%. Patients with PVs in non-breast-cancer risk genes were combined in a different category (21/82; 25.6%) (i.e., “non-associated gene carriers” group, considered other breast cancer cases). Median follow-up was 38.1 months, and 24% experienced recurrence, with 90% being distant. The 5-year Disease-Free Survival (DFS) for inherited breast cancer cases was 66.5%, and for other breast cancer cases it was 88.2%. In particular, for carriers of PVs in the BRCA2 gene, it was 37.6%. The 5-year Overall Survival (OS) rates ranged from 68.8% for those with PVs in BRCA2 to 100% for those with PVs in other HR-DDR genes. Further studies are crucial for understanding tumor behavior and therapy response differences among Colombian breast cancer patients with germline PVs.
- Open Access
- 26 March 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (4) , 1725-1738
Prognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference Cancer Center
Introduction: Soft tissue sarcomas (STS) are low-incidence tumors whose clinical and histopathological factors are associated with adverse oncological outcomes. This study evaluated prognostic factors (PF) associated with tumor recurrence and overall survival (OS) in patients diagnosed with STS of the extremities, treated at the Instituto Nacional de Cancerología (INC), Bogotá, Colombia. Materials and Methods: An analytical observational study of a historical cohort was carried out, including patients diagnosed with STS and managed surgically in the Functional Unit for Breast and Soft Tissue Tumors of the INC from January 2008 to December 2018. Results: A total of 227 patients were included; 74.5% had tumors greater than 5 cm. Most patients (29.1%) were in stage IIIB at diagnosis. Age was associated with higher mortality (HR = 1.01; CI95%: 1–1.02; p = 0.048). Tumor persistence at admission to the INC (HR = 2.34; CI95%: 1.25–4.35; p = 0.007) and histologic grade III (HR = 5.36; CI95%: 2.29–12.56; p = p = 0.014 and HR = 6.09; CI95%: 2.03–18.2; p = 0.001), respectively. Tumor size (HR = 1.03; CI95%: 1–1.06; p = 0.015) and histologic grade III (HR = 4.53; CI95%: 1.42–14.49; p = 0.011) were associated with a higher risk of distant recurrence. Conclusions: This cohort showed that in addition to histologic grade and tumor size, tumor persistence at the time of admission has an impact on disease recurrence, so STS should be managed by a multidisciplinary team with experience in this pathology in high-volume reference centers.
- 26 March 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (4) , 1725-1738
Open AccessPrognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference Cancer Center
Introduction: Soft tissue sarcomas (STS) are low-incidence tumors whose clinical and histopathological factors are associated with adverse oncological outcomes. This study evaluated prognostic factors (PF) associated with tumor recurrence and overall survival (OS) in patients diagnosed with STS of the extremities, treated at the Instituto Nacional de Cancerología (INC), Bogotá, Colombia. Materials and Methods: An analytical observational study of a historical cohort was carried out, including patients diagnosed with STS and managed surgically in the Functional Unit for Breast and Soft Tissue Tumors of the INC from January 2008 to December 2018. Results: A total of 227 patients were included; 74.5% had tumors greater than 5 cm. Most patients (29.1%) were in stage IIIB at diagnosis. Age was associated with higher mortality (HR = 1.01; CI95%: 1–1.02; p = 0.048). Tumor persistence at admission to the INC (HR = 2.34; CI95%: 1.25–4.35; p = 0.007) and histologic grade III (HR = 5.36; CI95%: 2.29–12.56; p = p = 0.014 and HR = 6.09; CI95%: 2.03–18.2; p = 0.001), respectively. Tumor size (HR = 1.03; CI95%: 1–1.06; p = 0.015) and histologic grade III (HR = 4.53; CI95%: 1.42–14.49; p = 0.011) were associated with a higher risk of distant recurrence. Conclusions: This cohort showed that in addition to histologic grade and tumor size, tumor persistence at the time of admission has an impact on disease recurrence, so STS should be managed by a multidisciplinary team with experience in this pathology in high-volume reference centers.
- 1 November 2023
- Published by CSurgeries in CSurgeries
Bleb Needling in Trabeculectomy Revision
Watch a video of a live Bleb Needling in Trabeculectomy Revision procedure in addition to hundreds more peer-reviewed surgical video journals - only at CSurgeries.com
- 1 November 2023
- Published by CSurgeries in CSurgeries
Bleb Needling in Trabeculectomy Revision
Watch a video of a live Bleb Needling in Trabeculectomy Revision procedure in addition to hundreds more peer-reviewed surgical video journals - only at CSurgeries.com